Overview

Bringing new therapies to patients typically takes more than a decade and on average costs $2.6B per new drug. Despite this investment, just 12% of clinical trials result in an approved treatment. While increased collaboration and investment across a range of disease fields promises to accelerate the pace and reduce costs, there are many barriers to overcome. 

Philanthropy is a critical tool for improving human health, but donors often lack the expertise and tools needed to navigate intentionally rigorous and often complex research and clinical ecosystems. SPARC advisors, in partnership with high-impact philanthropists, have been working across the scientific ecosystem to identify barriers to progress and pinpoint opportunities to strategically engage in the therapeutic development space.  

New Therapies
Related Content

Philanthropy News Digest Article

And Then There Were Three: Philanthropy’s Role in ALS Drug Development

Supporting new ideas and fresh perspectives, building critical research infrastructure to accelerate progress, and spurring cohesion and community-building by bringing people together are just some of the ways philanthropy can be transformational for ALS.
Read Article
Most people who are diagnosed with ALS only survive for two to five years. While the disease was first identified in 1869, the medical and scientific fields still lack critical knowledge about its causes and origins in most people.
Sylvie Raver, Director, Philanthropy, Milken Institute